Fabrazyme (agalsidase beta)
ApprovedProtein / enzyme
SanofiFabrazyme (agalsidase beta) is one of 62 biologic programs targeting Fabry Disease. It is currently in Approved.
2
Indications
6
Total Trials
0
Active Trials
61
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
119 competitors in Renal Insufficiency
#DrugCompanyPhaseTrials
1Galvus
NovartisPhase 3
Afinitor
NovartisPhase 3
Januvia
ZZydus Therapeutics Inc.
Phase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Calcineurin Inhibitors
SanofiPhase 3
Cysteine Hydrochloride
NovartisPhase 2
Decadron
AAspen Global Incorporated
Phase 2
Velcade
SShilpa Grover, MD, MPH
Phase 2
Fabrazyme (agalsidase beta)
SanofiApproved
Pomalyst
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Fabry Disease4 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fabrazyme (agalsidase beta). EMBL-EBI & Wellcome Sanger Institute.
- [4]